Correction to: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (Nature Communications, (2023), 14, 1, (4444), 10.1038/s41467-023-40061-y)

R. C. Coombes; Sacha Howell; Simon R. Lord; Laura Kenny; Janine Mansi; Zahi Mitri; Carlo Palmieri; Linnea I. Chap; Paul Richards; William Gradishar; Sagar Sardesai; Jason Melear; Joyce O’Shaughnessy; Patrick Ward; Pavani Chalasani; Tobias Arkenau; Richard D. Baird; Rinath Jeselsohn; Simak Ali; Glen Clack; Ashwani Bahl; Stuart McIntosh; Matthew G. Krebs

doi:10.1038/s41467-025-57535-w

Correction to: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (Nature Communications, (2023), 14, 1, (4444), 10.1038/s41467-023-40061-y)

R. C. Coombes
, Sacha Howell
, Simon R. Lord
, Laura Kenny
, Janine Mansi
, Zahi Mitri
, Carlo Palmieri
, Linnea I. Chap
, Paul Richards
, William Gradishar
, Sagar Sardesai
, Jason Melear
, Joyce O’Shaughnessy
, Patrick Ward
, Pavani Chalasani
, Tobias Arkenau
, Richard D. Baird
, Rinath Jeselsohn
, Simak Ali
, Glen Clack

Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Correction to: Nature Communicationshttps://doi.org/10.1038/s41467-023-40061-y, published online 24 July 2023 In the version of the article initially published, there was an error in the Table 3 rows reporting progression-free survival for patients without liver metastases, which, now reading “No liver metastases (N = 17); 13.8 (7.4, NC),” appeared originally as “No liver metastases (N = 17); 11.1 (1.7, NC),” while in the row now reading “Liver metastases (N = 14); 2.8 (1.8, 7.4)” the row originally read “Liver metastases (N = 14); 2.8 (1.8, 5.3)” The change is reflected in the HTML and PDF versions of the article.

Original language	English (US)
Article number	2242
Journal	Nature communications
Volume	16
Issue number	1
DOIs	https://doi.org/10.1038/s41467-025-57535-w
State	Published - Dec 2025
Externally published	Yes

ASJC Scopus subject areas

General Chemistry
General Biochemistry, Genetics and Molecular Biology
General Physics and Astronomy

Access to Document

10.1038/s41467-025-57535-w

Fingerprint

Dive into the research topics of 'Correction to: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (Nature Communications, (2023), 14, 1, (4444), 10.1038/s41467-023-40061-y)'. Together they form a unique fingerprint.

Cite this

Coombes, R. C., Howell, S., Lord, S. R., Kenny, L., Mansi, J., Mitri, Z., Palmieri, C., Chap, L. I., Richards, P., Gradishar, W., Sardesai, S., Melear, J., O’Shaughnessy, J., Ward, P., Chalasani, P., Arkenau, T., Baird, R. D., Jeselsohn, R., Ali, S., ... Krebs, M. G. (2025). Correction to: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (Nature Communications, (2023), 14, 1, (4444), 10.1038/s41467-023-40061-y). Nature communications, 16(1), Article 2242. https://doi.org/10.1038/s41467-025-57535-w

Correction to: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (Nature Communications, (2023), 14, 1, (4444), 10.1038/s41467-023-40061-y). / Coombes, R. C.; Howell, Sacha; Lord, Simon R. et al.
In: Nature communications, Vol. 16, No. 1, 2242, 12.2025.

Research output: Contribution to journal › Comment/debate › peer-review

Coombes, RC, Howell, S, Lord, SR, Kenny, L, Mansi, J, Mitri, Z, Palmieri, C, Chap, LI, Richards, P, Gradishar, W, Sardesai, S, Melear, J, O’Shaughnessy, J, Ward, P, Chalasani, P, Arkenau, T, Baird, RD, Jeselsohn, R, Ali, S, Clack, G, Bahl, A, McIntosh, S & Krebs, MG 2025, 'Correction to: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (Nature Communications, (2023), 14, 1, (4444), 10.1038/s41467-023-40061-y)', Nature communications, vol. 16, no. 1, 2242. https://doi.org/10.1038/s41467-025-57535-w

@article{f36d7a6037e942eca9173e4c2dcd9bd3,

title = "Correction to: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (Nature Communications, (2023), 14, 1, (4444), 10.1038/s41467-023-40061-y)",

abstract = "Correction to: Nature Communicationshttps://doi.org/10.1038/s41467-023-40061-y, published online 24 July 2023 In the version of the article initially published, there was an error in the Table 3 rows reporting progression-free survival for patients without liver metastases, which, now reading “No liver metastases (N = 17); 13.8 (7.4, NC),” appeared originally as “No liver metastases (N = 17); 11.1 (1.7, NC),” while in the row now reading “Liver metastases (N = 14); 2.8 (1.8, 7.4)” the row originally read “Liver metastases (N = 14); 2.8 (1.8, 5.3)” The change is reflected in the HTML and PDF versions of the article.",

author = "Coombes, \{R. C.\} and Sacha Howell and Lord, \{Simon R.\} and Laura Kenny and Janine Mansi and Zahi Mitri and Carlo Palmieri and Chap, \{Linnea I.\} and Paul Richards and William Gradishar and Sagar Sardesai and Jason Melear and Joyce O{\textquoteright}Shaughnessy and Patrick Ward and Pavani Chalasani and Tobias Arkenau and Baird, \{Richard D.\} and Rinath Jeselsohn and Simak Ali and Glen Clack and Ashwani Bahl and Stuart McIntosh and Krebs, \{Matthew G.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = dec,

doi = "10.1038/s41467-025-57535-w",

language = "English (US)",

volume = "16",

journal = "Nature communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Correction to

T2 - Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (Nature Communications, (2023), 14, 1, (4444), 10.1038/s41467-023-40061-y)

AU - Coombes, R. C.

AU - Howell, Sacha

AU - Lord, Simon R.

AU - Kenny, Laura

AU - Mansi, Janine

AU - Mitri, Zahi

AU - Palmieri, Carlo

AU - Chap, Linnea I.

AU - Richards, Paul

AU - Gradishar, William

AU - Sardesai, Sagar

AU - Melear, Jason

AU - O’Shaughnessy, Joyce

AU - Ward, Patrick

AU - Chalasani, Pavani

AU - Arkenau, Tobias

AU - Baird, Richard D.

AU - Jeselsohn, Rinath

AU - Ali, Simak

AU - Clack, Glen

AU - Bahl, Ashwani

AU - McIntosh, Stuart

AU - Krebs, Matthew G.

PY - 2025/12

Y1 - 2025/12

N2 - Correction to: Nature Communicationshttps://doi.org/10.1038/s41467-023-40061-y, published online 24 July 2023 In the version of the article initially published, there was an error in the Table 3 rows reporting progression-free survival for patients without liver metastases, which, now reading “No liver metastases (N = 17); 13.8 (7.4, NC),” appeared originally as “No liver metastases (N = 17); 11.1 (1.7, NC),” while in the row now reading “Liver metastases (N = 14); 2.8 (1.8, 7.4)” the row originally read “Liver metastases (N = 14); 2.8 (1.8, 5.3)” The change is reflected in the HTML and PDF versions of the article.

AB - Correction to: Nature Communicationshttps://doi.org/10.1038/s41467-023-40061-y, published online 24 July 2023 In the version of the article initially published, there was an error in the Table 3 rows reporting progression-free survival for patients without liver metastases, which, now reading “No liver metastases (N = 17); 13.8 (7.4, NC),” appeared originally as “No liver metastases (N = 17); 11.1 (1.7, NC),” while in the row now reading “Liver metastases (N = 14); 2.8 (1.8, 7.4)” the row originally read “Liver metastases (N = 14); 2.8 (1.8, 5.3)” The change is reflected in the HTML and PDF versions of the article.

UR - https://www.scopus.com/pages/publications/86000682767

UR - https://www.scopus.com/pages/publications/86000682767#tab=citedBy

U2 - 10.1038/s41467-025-57535-w

DO - 10.1038/s41467-025-57535-w

M3 - Comment/debate

C2 - 40050276

AN - SCOPUS:86000682767

SN - 2041-1723

VL - 16

JO - Nature communications

JF - Nature communications

IS - 1

M1 - 2242

ER -

Correction to: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (Nature Communications, (2023), 14, 1, (4444), 10.1038/s41467-023-40061-y)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this